Tags

Type your tag names separated by a space and hit enter

Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors.

Abstract

The specific protein target of delta9-tetrahydrocannabinol (delta9-THC), the main active ingredient of Cannabis sativa L., was characterized from rat brain nearly 20 years ago, and several endogenous compounds and proteins comprising the endocannabinoid (eCB) system have since been discovered. It has become evident that the eCB system consists of at least two cannabinoid receptors (i.e. the CB1 and CB2 receptors), in addition to their endogenous ligands (the eCBs) and several enzymes involved in the biosynthesis and catabolism of the eCBs. The two well-established eCBs, N-arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG), are produced by neurons on demand, act near their sites of synthesis and are effectively metabolized by fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL), respectively. Inhibitors specifically targeting these enzymes could offer novel therapeutic approaches (e.g. for the treatment of pain and movement disorders). This MiniReview summarizes the literature concerning the potential therapeutic potential of FAAH and MGL inhibitors.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Pharmaceutical Chemistry, University of Kuopio, Kuopio, Finland. susanna.saario@uku.fi

    Source

    MeSH

    Amidohydrolases
    Animals
    Cannabinoid Receptor Modulators
    Endocannabinoids
    Enzyme Inhibitors
    Humans
    Hydrolysis
    Monoacylglycerol Lipases
    Movement Disorders
    Pain

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Review

    Language

    eng

    PubMed ID

    17910610

    Citation

    Saario, Susanna M., and Jarmo T. Laitinen. "Therapeutic Potential of Endocannabinoid-hydrolysing Enzyme Inhibitors." Basic & Clinical Pharmacology & Toxicology, vol. 101, no. 5, 2007, pp. 287-93.
    Saario SM, Laitinen JT. Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. Basic Clin Pharmacol Toxicol. 2007;101(5):287-93.
    Saario, S. M., & Laitinen, J. T. (2007). Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. Basic & Clinical Pharmacology & Toxicology, 101(5), pp. 287-93.
    Saario SM, Laitinen JT. Therapeutic Potential of Endocannabinoid-hydrolysing Enzyme Inhibitors. Basic Clin Pharmacol Toxicol. 2007;101(5):287-93. PubMed PMID: 17910610.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. AU - Saario,Susanna M, AU - Laitinen,Jarmo T, PY - 2007/10/4/pubmed PY - 2007/12/6/medline PY - 2007/10/4/entrez SP - 287 EP - 93 JF - Basic & clinical pharmacology & toxicology JO - Basic Clin. Pharmacol. Toxicol. VL - 101 IS - 5 N2 - The specific protein target of delta9-tetrahydrocannabinol (delta9-THC), the main active ingredient of Cannabis sativa L., was characterized from rat brain nearly 20 years ago, and several endogenous compounds and proteins comprising the endocannabinoid (eCB) system have since been discovered. It has become evident that the eCB system consists of at least two cannabinoid receptors (i.e. the CB1 and CB2 receptors), in addition to their endogenous ligands (the eCBs) and several enzymes involved in the biosynthesis and catabolism of the eCBs. The two well-established eCBs, N-arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG), are produced by neurons on demand, act near their sites of synthesis and are effectively metabolized by fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL), respectively. Inhibitors specifically targeting these enzymes could offer novel therapeutic approaches (e.g. for the treatment of pain and movement disorders). This MiniReview summarizes the literature concerning the potential therapeutic potential of FAAH and MGL inhibitors. SN - 1742-7835 UR - https://www.unboundmedicine.com/medline/citation/17910610/Therapeutic_potential_of_endocannabinoid_hydrolysing_enzyme_inhibitors_ L2 - https://doi.org/10.1111/j.1742-7843.2007.00130.x DB - PRIME DP - Unbound Medicine ER -